The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease by Ohrfelt, A et al.
RESEARCH Open Access
The pre-synaptic vesicle protein
synaptotagmin is a novel biomarker for
Alzheimer’s disease
Annika Öhrfelt1* , Ann Brinkmalm1,2, Julien Dumurgier3, Gunnar Brinkmalm1, Oskar Hansson4,5,
Henrik Zetterberg1,2,6, Elodie Bouaziz-Amar7, Jacques Hugon3, Claire Paquet3 and Kaj Blennow1,2
Abstract
Background: Synaptic degeneration is a central pathogenic event in Alzheimer’s disease that occurs early during
the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-1
appears to be essential for the maintenance of an intact synaptic transmission and cognitive function. Synaptotagmin-1
in cerebrospinal fluid is a candidate Alzheimer biomarker for synaptic dysfunction that also may correlate with
cognitive decline.
Methods: In this study, a novel mass spectrometry-based assay for measurement of cerebrospinal fluid synaptotagmin-1
was developed, and was evaluated in two independent sample sets of patients and controls. Sample set I included
cerebrospinal fluid samples from patients with dementia due to Alzheimer’s disease (N = 17, age 52–86 years),
patients with mild cognitive impairment due to Alzheimer’s disease (N = 5, age 62–88 years), and controls (N = 17, age
41–82 years). Sample set II included cerebrospinal fluid samples from patients with dementia due to Alzheimer’s
disease (N = 24, age 52–84 years), patients with mild cognitive impairment due to Alzheimer’s disease (N = 18,
age 58–83 years), and controls (N = 36, age 43–80 years).
Results: The reproducibility of the novel method showed coefficients of variation of the measured synaptotagmin-1
peptide 215–223 (VPYSELGGK) and peptide 238–245 (HDIIGEFK) of 14 % or below. In both investigated sample sets, the
CSF levels of synaptotagmin-1 were significantly increased in patients with dementia due to Alzheimer’s disease
(P ≤ 0.0001) and in patients with mild cognitive impairment due to Alzheimer’s disease (P < 0.001). In addition, in
sample set I the synaptotagmin-1 level was significantly higher in patients with mild cognitive impairment due to
Alzheimer’s disease compared with patients with dementia due to Alzheimer’s disease (P ≤ 0.05).
Conclusions: Cerebrospinal fluid synaptotagmin-1 is a promising biomarker to monitor synaptic dysfunction and
degeneration in Alzheimer’s disease that may be useful for clinical diagnosis, to monitor effect on synaptic
integrity by novel drug candidates, and to explore pathophysiology directly in patients with Alzheimer’s disease.
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Background
Alzheimer’s disease is characterized by intracellular
neurofibrillary tangles, extracellular accumulation of ag-
gregated amyloid-β, neuronal degeneration, and synaptic
loss [1]. Several cerebrospinal fluid (CSF) biomarkers for
Alzheimer’s disease are available, including total tau and
phosphorylated tau protein, reflecting neurodegenera-
tion and tau pathology, respectively, and amyloid-β1–42
reflecting deposition of the peptide into plaques [2, 3].
Numerous studies have consistently shown a marked in-
crease in CSF total tau and phosphorylated tau accom-
panied by a reduction in amyloid-β1–42 in Alzheimer’s
disease, and also in the mild cognitive impairment (MCI)
stage of the disease [2, 3].
The leading hypothesis on Alzheimer’s disease patho-
genesis poses that accumulation of amyloid-β in the brain
is the primary driving force that causes synaptic failure
and neurodegeneration, which leads to progressive cogni-
tive deficits [4, 5]. The accumulation into amyloid-β may
occur as early as 20–30 years before the first cognitive
symptoms [6]. Synaptic degeneration in Alzheimer’s dis-
ease is related to cognitive decline [7–10] and synaptic loss
occurs early in the disease [11, 12]. Therefore, synaptic
biomarkers could be valuable tools for the disease, reflect-
ing synaptic dysfunction, degeneration, or loss. In recent
years, promising results have been published for some
synaptic biomarkers in CSF, including the pre-synaptic
protein synaptosomal-associated protein 25 (SNAP-25)
[13] and the post-synaptic protein neurogranin [14]
(http://www.alzforum.org/alzbiomarker/meta-analysis/
alzheimers-disease-vs-control-neurogranin-csf). A marked
increase of these synaptic CSF markers were found in
dementia due to Alzheimer’s disease and in MCI due
to Alzheimer’s disease, with higher CSF levels correlat-
ing with more marked future cognitive decline among
MCI patients [13, 14].
Disruption of synaptic transmission may account for
neuronal dysfunction and neurodegeneration. Synapto-
tagmin-1 is a pre-synaptic calcium sensor protein indis-
pensable for synaptic vesicle exocytosis mediating
neurotransmitter release in hippocampal neurons [15–18].
Efficient sustained neurotransmitter release is also
dependent on reformation of synaptic vesicles after
stimulation by endocytosis, where synaptotagmin-1 is
functioning as an essential vesicle cargo molecule [18].
The crucial function of syntaptotagmin-1 in synaptic
transmission [18–20] makes it a potential biomarker
candidate reflecting synaptic dysfunction and degen-
eration in Alzheimer’s disease. Indeed, several studies
have found a marked reduction of synaptotagmin-1
in typical disease-affected cortical brain regions in
Alzheimer’s disease [21, 22] and a colocalization of
synaptotagmin-1 with neuritic plaques [23]. We have
previously shown that synaptotagmin is present in CSF
[24], but until now there has not been any available
assay for assessment of synaptotagmin in individual
CSF samples.
In this study we report a novel mass spectrometry-
based assay for measurement of the pre-synaptic protein
synaptotagmin-1 in CSF. The aim of the study was to in-
vestigate the potential of synaptotagmin-1 as a CSF bio-
marker in dementia due to Alzheimer’s disease and in
MCI due to Alzheimer’s disease. Because synaptic degen-
eration is a prominent feature in the brain in Alzheimer’s
disease, we expected synaptotagmin-1 to be altered in
these patients compared with controls and therefore it
might serve as a valuable biomarker for Alzheimer’s
disease.
Methods
CSF samples
The reproducibility of the analytical method was investi-
gated in pooled left-over aliquots from decoded CSF
samples supplied by the clinical routine section at the
Clinical Neurochemistry Laboratory, The Sahlgrenska
University Hospital, Mölndal, Sweden, following proce-
dures approved by the Ethical Committee at University
of Gothenburg. The quality control CSF pool 1 (QC1
sample) had an amyloid-β1–42 level of 586 ng/L and a
total tau level below 75 ng/L. The QC2 sample had an
amyloid-β1–42 level of 129 ng/L, a total tau level below
75 ng/L, and a phosphorylated tau level below 15 ng/L.
Selection of the patients
CSF samples from subjects with either dementia due to
Alzheimer’s disease or MCI due to Alzheimer’s disease
or from a neurological control group were obtained from
the Research Memory Center at Lariboisière Fernand-
Widal University Hospital APHP. This department is
highly experienced in the care management of patients
with cognitive disorders and neurodegenerative disease,
and has used CSF biomarkers for a long period of time
[25–27]. Patients underwent a comprehensive clinical
examination including personal medical and family histor-
ies, neurological examination, neuropsychological assess-
ment, lumbar puncture with CSF biomarker analysis, and
a brain structural imaging study with MRI. A consensus
diagnosis was made by several clinicians (neurologists,
geriatricians), neuropsychologists, and a biologist who are
experts in CSF biomarkers. For each patient, diagnosis
was made considering CSF results and according to val-
idated clinical diagnostic criteria for dementia due to
Alzheimer’s disease [28], MCI due to Alzheimer’s dis-
ease [29, 30], subjective cognitive impairment [31], and
psychiatric disorder (DSM-IV). For all patients, diagno-
ses were validated in a second step by a neurologist
(CP) and a biochemist (EB-A) before selecting CSF
samples. In the absence of consensus diagnosis and in
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cases of disagreement about the final diagnosis, patients
were not included in the study. According to this method,
CSF from subjects with dementia due to Alzheimer’s dis-
ease, subjects with MCI due to Alzheimer’s disease, and
neurological controls (no neurodegenerative disorders)
was selected. Two sample sets were explored. Recently,
the Alzheimer’s disease core CSF biomarkers have been
included in the research criteria for the diagnosis of both
early and manifest AD by the International Working
Group [29] and in the diagnostic guidelines from the
National Institute on Aging–Alzheimer’s Association
[28], respectively. The following cutoff values were used
to define a biochemical Alzheimer’s disease signature as
supportive criteria for dementia due to Alzheimer’s disease
[28]: amyloid-β1–42 (<550 ng/L), total tau (>400 ng/L), and
phosphorylated tau (>50 ng/L). These criteria was also ap-
plied to exclude other diseases and to specify the controls.
Sample set I included patients who underwent a lumbar
puncture between 2010 and 2012, while sample set II in-
cluded patients from 2013 to 2015 (Table 1).
CSF collection
CSF was obtained by lumbar puncture between the L3/
L4 or L4/L5 intervertebral space, using an atraumatic
24-gauge needle, collected in 10-mL polypropylene
tubes. Samples were centrifuged at 1800 × g for 10 mi-
nutes at +4 °C, were aliquoted in 500 μL polypropylene
tubes, and were stored at –80 °C pending analysis.
Samples were frozen at −80 °C within 1 h after collec-
tion according to a standardized protocol described in
a previous report [26]. A small amount of CSF was
used for routine analysis, including total cell count,
bacteriologic examination, and total protein and glu-
cose levels.
Analysis of CSF biomarkers
Amyloid-β1–42, total tau, and tau phosphorylated at
threonine 181 (phosphorylated tau) protein measure-
ments were performed using commercially available as-
says from Fujirebio (INNOTEST® β-AMYLOID(1-42),
INNOTEST® hTAU Ag, and INNOTEST® PHOSPHO-
TAU(181P)) according to the manufacturer’s instruc-
tions. For the two sample sets, the analysis of these bio-
markers was performed in a single hospital laboratory
(Lariboisère Hospital Paris) in two runs and averaged re-
sults were used for statistical analyses. The quality of
CSF evaluations was validated by the Alzheimer’s Asso-
ciation quality control program for CSF biomarkers [32].
Antibodies and recombinant protein of synaptotagmin-1
The monoclonal antibody clone 41.1 recognizing the
cytoplasmic portion of synaptotagmin-1 was purchased
from Synaptic Systems (Göttingen, Germany). Recom-
binant protein of synaptotagmin-1 (catalog number
TP327252), transcript variant 3, was from OriGene
Technologies, Inc. (Rockville, MD, USA).
Immunoprecipitation
The immunoprecipitation method for CSF samples was
performed according to Brinkmalm et al. [13] with
minor modifications. Briefly, an aliquot (1 μg) of the
mouse monoclonal synaptotagmin-1 antibody clone 41.1
Table 1 Demographic data and biomarker CSF levels for the diagnostic groupsa
Control MCI-AD Alzheimer’s disease dementia
Sample set I
Number (men/women) 17 (7/10) 5 (1/4) 17 (5/12)
Age (years) 60 (53–67), P = 0.02c 78 (73–81), P = 0.02b 65 (58–81)
MMSE 27 (24–28) 27 (27–28) 21 (16–23), P = 0.00001b, P = 0.004c
Amyloid-β1–42 (ng/L) 838 (697–998), P = 0.001c 539 (316–582), P = 0.001b 398 (319–483), P < 0.00001b
Total tau (ng/L) 180 (126–206), P = 0.00008c 1000 (766–1078), P = 0.00008b 602 (442–769), P < 0.00001b
Phosphorylated tau (ng/L) 39 (35–42), P = 0.00008c 143 (97–180), P = 0.00008b 89 (75–119), P < 0.00001b
Sample set II
Number (men/women) 36 (13/23) 18 (5/13) 24 (7/17)
Age (years) 62 (55–69), P = 0.001c 70 (69–78), P = 0.001b 68 (64–72), P = 0.02b
MMSE 28 (26–29) 27 (26–28) 22 (17–24), P = 0.00001b, P = 0.00001c
Amyloid-β1–42 (ng/L) 971 (844–1110), P < 0.00001c 558 (377–667), P < 0.00001b 497 (459–571), P < 0.00001b
Total tau (ng/L) 197 (157–227), P < 0.00001c 570 (520–717), P < 0.00001b 623 (527–799), P < 0.00001b
Phosphorylated tau (ng/L) 40 (32–46), P < 0.00001c 86 (79–104), P < 0.00001b 91 (73–115), P < 0.00001b
aData given as median (interquartile range) unless otherwise indicated. Statistical differences were determined using nonparametric tests
bCompared with controls
cCompared with MCI-AD
MCI-AD mild cognitive impairment due to Alzheimer’s disease, MMSE Mini-Mental State Examination
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(1 g/L) or IgG from murine serum (1 g/L, a negative
control; Sigma-Aldrich) was separately added to 50 μL
magnetic Dynabeads M-280 Sheep anti-mouse IgG (Invi-
trogen Corporation) and incubated for 1 h on a rocking
platform at room temperature. The beads were washed
three times with 1 ml of phosphate-buffered saline
(PBS). The antibodies were cross-linked using 20 mM
dimethyl pimelimidate dihydrochloride (Sigma-Aldrich)
and 0.2 M triethanolamine (pH 8.2; Sigma-Aldrich) ac-
cording to the manufacturer’s product description. The
cross-linked beads were washed twice in PBS and were
blocked with Roti-Block (Carl Roth) for 1 h on a rocking
platform at room temperature. CSF samples (250 μL)
were adjusted with 5 % Tween 20 and PBS to a final
concentration of 0.05 % Tween 20 and a final volume of
1 mL. Samples and magnetic beads were incubated over-
night on a rocking platform at +4 °C. The magnetic
beads/sample solution was transferred to the KingFisher
magnetic particle processor (Thermo Fisher Scientific),
tube 1. The following three wash steps (tubes 2–4) were
conducted for 10 s in 1 mL of each washing buffer: (tube
2) 0.025 % Tween 20 in PBS, (tube 3) PBS, and (tube 4)
50 mM ammonium hydrogen carbonate (NH4HCO3,
pH 8.0). Synaptotagmin-1 was then eluted from the
beads by adding 100 μL of 0.5 % formic acid (tube 5) for
4 min. The eluted fractions were transferred to 0.65 mL
prelubricated Costar Microcentrifuge Tube (Fisher Sci-
entific) and dried in a vacuum centrifuge.
Protein digestion and addition of heavy-isotope-labeled
peptide standards
Two isotopically labeled custom-made peptides contain-
ing U-13C6, U-15 N2-lysine[K] (aa 215–223, VPY-
SELGG[K] and aa 238–245, HDIIGEFK HeavyPeptide
FasTrack 1 standards; Thermo Fisher Scientific) were
dissolved in MilliQ water (~500 pmol/μL), mixed, and
diluted in 50 mM NH4HCO3 to a final concentration of
~10 fmol/μL. The dried immunoprecipitated CSF sam-
ples were dissolved in 25 μL of a mixture of trypsin and
labeled peptides (1 μg Sequencing Grade Modified Tryp-
sin (Promega) dissolved in 0.01 % aqueous HCl (0.1 g/L)
and diluted to 5 mg/L in isotopically labeled peptide
mixture in 50 mM NH4HCO3, pH ≈ 7.8 (see earlier)),
vortexed carefully, and incubated at +37 °C overnight.
To stop the enzymatic activity, 5 μL of 10 % aqueous FA
was added. The samples were centrifuged (16,900 × g,
10 min, +4 °C) and 27 μL of each sample was transferred
to LC-vials (SUN-SRi).
High-resolution parallel reaction monitoring analyses
High-resolution parallel reaction monitoring (HR-PRM)
analyses were performed on a Q Exactive quadrupole–
orbitrap mass spectrometer (Thermo Fisher Scientific)
coupled to an Ultimate 3000 standard liquid chromatog-
raphy system (Thermo Fisher Scientific). The samples
(25 μL) were loaded directly onto a Hypersil GOLD
HPLC C18 column (length 100 mm; inner diameter
2.1 mm; particle size 1.9 μm; Thermo Fisher Scientific)
with 0.1 % aqueous formic acid at 100 μL/min. Mobile
phases were: A, 0.1 % formic acid in water (v/v); and B,
0.1 % formic acid and 84 % acetonitrile in water (v/v).
The peptides were eluted off the column using the fol-
lowing linear gradient steps: 1 min, 0 % B; 3 min, 12 %
B; 11 min, 40 % B; and 13 min, 100 % B. The IonMax
electrospray ion source settings were: spray voltage,
+4100 V; capillary temperature, +320 °C; sheath gas
pressure setting, 25 arbitrary units; auxiliary gas pressure
setting, 10 arbitrary units; and heater temperature, +300 °C.
The instrument was set to acquire scheduled pairs of
SIM scans and subsequently all ion fragmentation scans
(isolation window 8.0m/z) in profile mode, allowing
simultaneous detection of both the synaptotagmin pep-
tide and the corresponding isotopically labeled peptide
standard. The settings were common for both scan
types and were as follows: resolution setting, 35,000;
AGC target, 1e6; maximum injection time, 120 ms. Data
acquisition and analysis were performed with Xcalibar
software version 2.2 SP1.48 (Thermo Fisher Scientific).
Assay reproducibility
The intra-day variation of synaptotagmin was deter-
mined using two QC samples (QC1 and QC2). The im-
munoprecipitation of synaptotagmin-1 from the QC
samples were performed on different days but analyzed
on the same occasion. Assessment of reproducibility was
performed on two different occasions, and QC samples
were randomized in between samples from sample set I
(first occasion) and sample set II (second occasion).
Statistical analysis
Because most of the analytes were not normally distrib-
uted (Shapiro–Wilk test, P < 0.05), nonparametric statis-
tics were used for analysis. Data are given as the median
(interquartile range). Differences between more than two
groups were assessed with Kruskal–Wallis test. Statisti-
cally significant results (P < 0.05) were followed by
Mann–Whitney U tests to investigate group differences.
Receiver operating characteristic (ROC) curves were per-
formed on each subject group on the tryptic peptides of
synaptotagmin-1 in order to assess their diagnostic
value. For each tryptic peptide of synaptotagmin, the
area under the curve and a 95 % confidence interval was
calculated using GraphPad Prism 5. The correlation co-
efficients (rho) were calculated using the Spearman two-
tailed correlation test. SPSS 20.0 was employed for most
of the statistical analyses.
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Results
Assay performance
The reproducibility of the novel method showed coeffi-
cients of variation (CV) of the measured synaptotagmin-1
peptide 215–223 (VPYSELGGK) and peptide 238–245
(HDIIGEFK) of 14 % or below (Additional file 1: Table
S1). The investigated tryptic peptides correlated with each
other in the groups of controls (rho = 0.971, P < 0.00001,
sample set I; and rho = 0.995, P < 0.00001, sample set II),
MCI due to Alzheimer’s disease (rho = 0.988, P < 0.00001,
sample set II; sample set I was too small for statistical
evaluation), and dementia due to Alzheimer’s disease
(rho = 0.980, P < 0.00001, sample set I; and rho = 0.995,
P < 0.00001, sample set II) (Table 2).
Clinical studies
Demographics
Table 1 presents the demographic characteristics of the
groups. Sample set I consisted of five patients with MCI
due to Alzheimer’s disease (one man and four women,
age 62–88 years), 17 patients with dementia due to Alz-
heimer’s disease (five men and 12 women, age 52–86
years), and 17 neurological controls (seven men and 10
women, age 41–82 years). The replication sample set
(sample set II) consisted of 18 patients with MCI due to
Alzheimer’s disease (five men and 13 women, age 58–83
years), 24 patients with dementia due to Alzheimer’s dis-
ease (seven men and 17 females, age 52–84 years), and
36 neurological controls (13 men and 23 women, age
43–80 years). In sample set I, the patients with MCI due
to Alzheimer’s disease were older than the subjects with
controls. Both patients with MCI due to Alzheimer’s dis-
ease and patients with dementia due to Alzheimer’s dis-
ease were significantly older than the subjects with
controls in sample set II. All patients from the neuro-
logical control group had cognitive complaints (group I,
N = 14 and group II, N = 25) or had psychiatric diagnoses
(group I, N = 3 and group II, N = 11). To rule out pre-
clinical Alzheimer’s disease in the neurological control
group, only cases with normal CSF levels amyloid-β1–42
(>550 ng/L), total tau (<400 ng/L), and phosphorylated
tau (<50 ng/L) were included.
The CSF levels of the investigated tryptic peptides of
synaptotagmin-1 were significantly higher in patients
with MCI due to Alzheimer’s disease and patients with
dementia due to Alzheimer’s disease compared with
controls (Fig. 1). In sample set I, the tryptic peptides of
synaptotagmin-1 were significantly higher in patients with
MCI due to Alzheimer’s disease compared with patients
with dementia due to Alzheimer’s disease (Fig. 1a, b).
Each of the tryptic peptide assays of synaptotagmin-1
(215–223 and 238–245) could differentiate MCI due to
Alzheimer’s disease from controls in both sample sets, with
area under the curve of 0.988 (0.952–1.025) (P = 0.001) and
1.000 (1.000–1.000) (P = 0.0009) (sample set I), respectively,
and of 0.813 (0.692–0.934) (P = 0.0002) and 0.801 (0.676–
0.926) (P = 0.0003) (sample set II), respectively (Fig. 2a).
The tryptic peptide assays of synaptotagmin-1 (215–223
and 238–245) could also each differentiate dementia due to
Alzheimer’s disease from controls in both sample sets, with
area under the curve of 0.886 (0.755–1.017) (P = 0.0001)
and 0.893 (0.770–1.016) (P < 0.0001) (sample set I), respect-
ively, and of 0.815 (0.703–0.926) (P < 0.0001) and 0.795
(0.679–0.912) (P = 0.0001) (sample set II), respectively
(Fig. 2b).
No statistically significant correlations between age
and the levels of the tryptic peptides of synaptotagmin
were observed in any of the investigated groups (Table 2).
There were no statistical significant correlations between
CSF synaptotagmin-1 and Mini-Mental State Examin-
ation (MMSE) scores in any group.
The CSF levels of synaptotagmin (tryptic peptides
215–223 and 238–245) correlated with the levels of total
tau and phosphorylated tau in both the control group
(sample sets I and II) and in patients with dementia due
to Alzheimer’s disease (sample sets I and II), but not in
patients with MCI due to Alzheimer’s disease (sample
set II) (Table 2). Synaptotagmin-1 (215–223) correlated
with amyloid-β1-42 in the control group (rho = 0.515,
P = 0.04 and rho = 0.381, P = 0.02, respectively), but not
in patients with either MCI due to Alzheimer’s disease
or dementia due to Alzheimer’s disease (Table 2).
Synaptotagmin-1 (238–245) correlated only with amyloid-
β1-42 (rho = 0.348, P = 0.04) in the control group of sample
set II, while there were no correlations within other inves-
tigated groups (Table 2).
Discussion
In this study, we investigated the potential of
synaptotagmin-1 as a CSF biomarker in dementia due
to Alzheimer’s disease and in MCI due to Alzheimer’s
disease. Therefore, we developed novel assays for the
measurement of synaptotagmin-1, which is a pre-synaptic
vesicle protein indispensable for the regulation of synaptic
transmission and for sustaining intact cognitive function.
In the present study, we report that the levels of
synaptotagmin-1 were significantly increased in pa-
tients with MCI due to Alzheimer’s disease and patients
with dementia due to Alzheimer’s disease compared
with controls, supporting that synaptotagmin-1 could
be an early marker for Alzheimer’s disease.
The novel assay combines immunoprecipitation, tryptic
digestion and finally mass spectrometry (HR-PRM) for
analyses of the CSF levels of synaptotagmin, which is a
similar approach to that we applied successfully for quan-
tification of SNAP-25 in CSF [13]. Synaptotagmin-1
consists of an N-terminal intravesicular domain, a
transmembrane part, and a large cytoplasmic sequence
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Table 2 Correlation between age, MMSE, and biomarker levels for the diagnostic groupsa
Synaptotagmin, 215–223 Synaptotagmin, 238–245
Sample set I, control (N = 17)
Age N.S. N.S.
MMSE N.S. N.S.
Amyloid-β1–42 (ng/L) rho = 0.515, P = 0.04 N.S.
Total tau (ng/L) rho = 0.739, P = 0.001 rho = 0.749, P = 0.001
Phosphorylated tau (ng/L) rho = 0.770, P = 0003 rho = 0.708, P = 0.001
Synaptotagmin, 215–223 – rho = 0.971, P < 0.00001
Synaptotagmin, 238–245 rho = 0.971, P < 0.00001 –
Alzheimer’s disease dementia (N = 17)
Age N.S. N.S.
MMSE N.S. N.S.
Amyloid-β1–42 (ng/L) N.S. N.S.
Total tau (ng/L) rho = 0.540, P = 0.03 rho = 0.610, P = 0.009
Phosphorylated tau (ng/L) rho = 0.586, P = 0.01 rho = 0.656, P = 0.004
Synaptotagmin, 215–223 – rho = 0.980, P < 0.00001
Synaptotagmin, 238–245 rho = 0.980, P < 0.00001 –
Sample set II, control (N = 36)
Age N.S. N.S.
MMSE N.S. N.S.
Amyloid-β1–42 (ng/L) rho = 0.381, P = 0.02 rho = 0.348, P = 0.04
Total tau (ng/L) rho = 0.641, P = 0.00003 rho = 0.633, P = 0.00004
Phosphorylated tau (ng/L) rho = 0.687, P < 0.00001 rho = 0.683, P < 0.00001
Synaptotagmin, 215–223 – rho = 0.995, P < 0.00001
Synaptotagmin, 238–245 rho = 0.995, P < 0.00001 –
MCI-AD (N = 18)
Age N.S. N.S.
MMSE N.S. N.S.
Amyloid-β1–42 (ng/L) N.S. N.S.
Total tau (ng/L) N.S. N.S.
Phosphorylated tau (ng/L) N.S. N.S.
Synaptotagmin, 215–223 – rho = 0.988, P < 0.00001
Synaptotagmin, 238–245 rho = 0.988, P < 0.00001 –
Alzheimer’s disease dementia (N = 24)
Age N.S. N.S.
MMSE N.S. N.S.
Amyloid-β1–42 (ng/L) N.S. N.S.
Total tau (ng/L) rho = 0.655, P = 0.001 rho = 0.675, P = 0.0003
Phosphorylated tau (ng/L) rho = 0.653, P = 001 rho = 0.673, P = 0.0003
Synaptotagmin, 215–223 – rho = 0.995, P < 0.00001
Synaptotagmin, 238–245 rho = 0.995, P < 0.00001 –
aCorrelations presented by the Spearman’s rank correlation coefficient (rho). Nonsignificant (N.S., P > 0.05) correlations were not reported
MCI-AD mild cognitive impairment due to Alzheimer’s disease, MMSE Mini-Mental State Examination
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that contains two calcium (C2) binding domains. Both
tryptic peptides of the novel assays are located in the
first (C2A) of two calcium-binding domains of
synaptotagmin-1, domains of the protein that are es-
sential for appropriate synaptic transmission [16–18].
Furthermore, the novel mass spectrometry-based method
allows selective measurements of the synaptotagmin-1 iso-
form. Since the 17 members of the synaptotagmin family
are differently expressed throughout the body [33, 34] and
these isoforms exhibit diverse biological functions, the
ability to discriminate between them is certainly of great
importance for a valuable synaptic biomarker.
We found that the CSF levels of synaptotagmin-1 were
consistently elevated in patients with dementia due to Alz-
heimer’s disease compared with controls in two separate
sample sets. Additionally, synaptotagmin-1 was increased
already in MCI due to Alzheimer’s disease, supporting the
notion that this synaptic marker might be an early marker
for Alzheimer’s disease. These findings are in accordance
with our previous findings of the pre-synaptic marker
SNAP-25 [13] and the post-synaptic marker neurogranin
[14]. Furthermore, synaptotagmin-1 was even higher in
MCI due to Alzheimer’s disease compared with dementia
due to Alzheimer’s disease, suggesting that synaptic
dysfunction and degeneration can be identified before the
onset of clinical dementia [11, 12]. However, because this
latter finding was only supported by data from sample set I,
this notion needs to be taken with caution and needs to be
reproduced in a larger set of patients.
Each measured tryptic peptide of synaptotagmin-1
(215–223 and 238–245) could differentiate dementia
due to Alzheimer’s disease from controls and MCI due
to Alzheimer’s disease from controls to a similar magni-
tude, in the respective sample sets. The tryptic peptides
of synaptotagmin-1 assays also correlated with each
other in all investigated groups (controls, MCI due to
Alzheimer’s disease, and dementia due to Alzheimer’s
disease) in the respective sample sets. Moreover, the
reproducibility of the novel method (CV) was less
than 14 %. Altogether these findings support the no-
tion that each tryptic peptide corresponds to the same
synaptotagmin-1 molecule.
In both sample sets, the MCI due to Alzheimer’s disease
patients were significantly older than the controls. In
sample set I the patients with dementia due to Alzheimer’s
disease and the controls were age matched, while the pa-
tients with dementia due to Alzheimer’s disease were sig-
nificantly older than the controls in sample set II. On the
other hand, there were no statistically significant correla-
tions between age and the levels of synaptotagmin-1 in
Fig. 1 Targeted HR-PRM-MS analyses of synaptotagmin in human CSF. Individual values for the HR-PRM-MS measured peak area ratios ((endogenous
peptide/labeled peptide standard) × 1000) of immunoprecipitated synaptotagmin in CSF samples within sample set I (a, b) and sample set II (c, d). The
four panels depict the measured levels of two tryptic peptides of synaptotagmin, 215–223 (VPYSELGGK) (a, c) and 238–245 (HDIIGEFK) (b, d).
AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease
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any of the investigated groups, suggesting that the CSF
synaptotagmin-1 levels not are affected by age within the
age range of this study.
The mechanism for release of synaptotagmin-1 into
CSF is not known. However, it is interesting to note that
previous studies showed that C2 domains may penetrate
a cell membrane upon calcium binding [35, 36], which
could be a possible mechanism of liberation into CSF.
Herein, we found that synaptotagmin-1 correlated with
the levels of total tau and phosphorylated tau both in
the control group and in patients with dementia due to
Alzheimer’s disease in both investigated sample sets.
CSF total tau has previously been suggested to be a gen-
eral marker of damage to cortical nonmyelinated neu-
rons [2]. In contrast, phosphorylated tau might be a
more specific marker for Alzheimer’s disease [2], since
high CSF levels of phosphorylated tau have been found
to correlate with the accumulation of cortical neurofib-
rillary tangles [37, 38]. To summarize, our results sug-
gest that synaptotagmin-1 might be a specific marker for
dementia due to Alzheimer’s disease that to some extent
also might reflect general neurodegeneration.
The fact that synaptic loss is the main pathological fea-
ture of dementia due to Alzheimer’s disease that correlates
with cognitive decline, together with the notion that
synaptotagmin-1 is directly involved in the regulation of
neurotransmitter release [16, 18], make synaptotagmin-1 a
potential CSF biomarker to follow progression of clinical
symptoms. In the present study, there were no correla-
tions between cognitive decline and the tryptic peptides of
synaptotagmin-1 in any of the examined groups, possibly
due to the small size of the clinical sample sets. Further
studies are therefore needed to investigate whether
synaptotagmin-1 in CSF could be used for assessment of
the future rate of cognitive decline.
The strength of the present study is that we present
robust assays for assessment of the CSF levels of
synaptotagmin-1 in two independent sample sets. To our
knowledge this is the first study investigating the potential
of synaptotagmin-1 as a CSF biomarker for Alzheimer’s
disease. One limitation of the present study is the cross-
sectional design of the clinical study that complicates the
investigation of possible association between CSF synapto-
tagmin and synaptic degeneration. This question has to be
addressed by longitudinal measurements of synaptotag-
min to investigate whether the levels are changed over
time and whether it correlates with cognitive alterations in
patients with Alzheimer’s disease. Another limitation
could probably be that all clinical samples were analyzed
as single samples. Since the analytical reproducibility of
the method (CV < 14 %) yields very similar results for du-
plicates while the measured levels vary considerably be-
tween patients, we decided to include as many different
patients as possible and thereby try to obtain a more rep-
resentative picture of the biological variation rather than
the analytical.
Fig. 2 ROC curve analysis of synaptotagmin in human CSF. ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin
238–245 (turquoise and black) in CSF for differentiation of MCI due to Alzheimer’s disease (MCI-AD) from controls in sample set I and sample set II,
respectively (a). ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin 238–245 (turquoise and black) in CSF for
differentiation of dementia due to Alzheimer’s disease (AD) from controls in sample set I and sample set II, respectively (b). The area under the
curve (95 % confidence interval) is shown in the included table (c). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment
due to Alzheimer’s disease (Color figure online)
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Conclusions
We present a novel method for measurement of the
pre-synaptic protein synaptotagmin-1 in CSF samples.
Synaptotamin-1 concentrations were increased in pa-
tients with MCI due to Alzheimer’s disease and patients
with dementia due to Alzheimer’s disease compared with
controls, supporting the notion that synaptotagmin-1
could be a valuable differential biomarker both in early
Alzheimer’s disease and after manifestation of the disease.
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